Recently, Dhillon et al. measured IL-33 levels in 577 patients with NSTEMI and found no relation of IL-33 levels to adverse events such as all-cause mortality, heart failure hospitalization, and reinfarction [25]. This evidence concerns the gene IL33 and heart failure.